ArticleAdvances in experimental medicine and biology2021
The Intratumoral Heterogeneity of Cancer Metabolism.
Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tumour-Associated Neutrophils in Colorectal Cancer: a Systematic Review, Meta-analysis, and Comprehensive Literature Review.Journal of gastrointestinal cancer · 2026Pooled it
- Hyperpolarized [2-NMR in biomedicine · 2026Article
- Reversible dissociation of mitochondrial Complex V balances anabolic and energy-generating needs in cancer.iScience · 2026Article
- Deciphering cellular plasticity in pancreatic cancer for effective treatments.Cancer metastasis reviews · 2024Review
- Aiding Cancer's "Sweet Tooth": Role of Hexokinases in Metabolic Reprogramming.Life (Basel, Switzerland) · 2023Review
- Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma.International journal of molecular sciences · 2023Review
- Lipid Profiling in Cancer Diagnosis with Hand-Held Ambient Mass Spectrometry Probes: Addressing the Late-Stage Performance Concerns.Metabolites · 2021Review
- More Than Meets the Eye Regarding Cancer Metabolism.International journal of molecular sciences · 2021Review
- The Heterogeneity of Liver Cancer Metabolism.Advances in experimental medicine and biology · 2021Article
- Different Tumor Microenvironments Lead to Different Metabolic Phenotypes.Advances in experimental medicine and biology · 2021Article
- Metabolism of Immune Cells in the Tumor Microenvironment.Advances in experimental medicine and biology · 2021Article
- Metabolic Relationship Between Cancer-Associated Fibroblasts and Cancer Cells.Advances in experimental medicine and biology · 2021Article
- Targeting Metabolic Cross Talk Between Cancer Cells and Cancer-Associated Fibroblasts.Advances in experimental medicine and biology · 2021Article
- Metabolites Profiling of Melanoma Interstitial Fluids Reveals Uridine Diphosphate as Potent Immune Modulator Capable of Limiting Tumor Growth.Frontiers in cell and developmental biology · 2021Article
- Glucose Metabolism in Cancer: The Warburg Effect and Beyond.Advances in experimental medicine and biology · 2021Article
- Glutamine Metabolism in Cancer.Advances in experimental medicine and biology · 2021Article
- The Heterogeneity of Breast Cancer Metabolism.Advances in experimental medicine and biology · 2021Article
- The Heterogeneity of Lipid Metabolism in Cancer.Advances in experimental medicine and biology · 2021Article
- Non-Hodgkin Lymphoma Metabolism.Advances in experimental medicine and biology · 2021Article
- The Multifaceted Glioblastoma: From Genomic Alterations to Metabolic Adaptations.Advances in experimental medicine and biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the deadliest diseases in the world, causing over half a million deaths a year in the USA alone. Despite recent advances made in the field of cancer biology and the therapies that have been developed [1, 2], it is clear that more advances are necessary for us to classify cancer as curable. The logical question that arises is simple: Why, despite all the technologies and medical innovations of our time, has a complete cure eluded us? This chapter sheds light on one of cancer's most impactful attributes: its heterogeneity and, more specifically, the intratumoral heterogeneity of cancer metabolism. Simply put, what makes cancer one of the deadliest diseases is its ability to change and adapt. Cancer cells' rapid evolution, coupled with their irrepressible ability to divide, gives most of them the advantage over our immune systems. In this chapter, we delve into the complexities of this adaptability and the vital role that metabolism plays in the rise and progression of this heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.